SCHEMBL679345

SCHEMBL679345

CS(=O)(=O)NC(=O)c1ccc(Oc2cccc(C(F)(F)F)c2)c(C#N)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 9/20 0.51
MRGPRX4 Q96LA9 1/20 0.48
SCN5A Q14524 2/20 0.46
SCN2B O60939 1/20 0.46
SCN1A P35498 1/20 0.46
SCN1B Q07699 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
RECQL P46063 1/20 0.46
MAPT P10636 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
KDM4E B2RXH2 1/20 0.43
LMNA P02545 1/20 0.43
PTPN1 P18031 1/20 0.43
MCL1 Q07820 1/20 0.42
GAA P10253 1/20 0.42
MAPK1 P28482 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
PLA2G7 Q13093 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL680555 0.86 SLC22A12 (0.50) SCN9ASCN5ASCN2BSCN1ASCN1B
SCHEMBL680209 0.85 SCN9A (0.48) SCN9ASCN5ASCN2BSCN1ASCN1B
SCHEMBL680208 0.85 TBXA2R (0.49) SCN9ASCN5ASCN2BSCN1ASCN1B
SCHEMBL680193 0.84 MRGPRX4 (0.61) SCN9AMRGPRX4SCN5ASCN2BSCN1A
SCHEMBL679146 0.83 SCN9A (0.52) SCN9ASCN5AMCL1PLA2G7
SCHEMBL875976 0.82 NR4A2 (0.50) MRGPRX4CYP1A2CYP2C9CYP2C19RECQL
SCHEMBL679923 0.82 SCN3A (0.47) SCN9ASCN5ALMNA
SCHEMBL16319655 0.82 PLA2G7 (0.62) SCN9ASCN5APLA2G7
SCHEMBL680717 0.81 MAPK14 (0.56) SCN9AMRGPRX4SCN5ASCN2BSCN1A
SCHEMBL680479 0.81 SCN9A (0.50) SCN9AMRGPRX4SCN5APTPN1PLA2G7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2593427-B1 SULFONAMIDE DERIVATIVES AS NAV1.7 INHIBITORS FOR THE TREATMENT OF PAIN PFIZER LTD (GB) 2014-12-24 EP disclosed
US-20120010207-A1 Chemical Compounds PFIZER LIMITED (GB) 2012-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010207-A1 Chemical Compounds SCN1A, SCN1B, SCN7A SCN9A 13/4885MRGPRX4 344/4885SCN5A 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.